Management

To be or not to be…

Read more

Global biotech’s financial performance stabilising: EY report

Read more

FSSA and the emerging OTC landscape

Read more

Regulatory woes of pharma SMEs

Read more

ACTA Down, but What Next?

Read more

Drug pricing norms: Cost or MRP based?

Read more

Venus Remedies: Reinventing R&D

Read more

Regulatory woes of pharma SMEs (Part I)

Read more

Back to the roots —Landscaping OTC opportunities in the Indian ayurveda market

Read more

A holistic view of the HPAPI opportunity

Read more